Taysha Gene Therapies (TSHA) Operating Expenses (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Operating Expenses data on file, last reported at $43.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 83.31% year-over-year to $43.5 million; the trailing twelve-month figure through Mar 2026 stood at $140.0 million (up 46.21% YoY), and the FY2025 full-year result was $120.3 million, up 20.52% from the prior year.
• Operating Expenses advanced to $43.5 million in Q1 2026, from $33.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $56.5 million in Q4 2022 to a low of $19.8 million in Q4 2023.
• A 5-year average of $30.4 million and a median of $27.7 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses plunged 64.85% in 2023 and soared 83.31% in 2026, its largest moves.
• Tracing TSHA's Operating Expenses over 5 years: stood at $56.5 million in 2022, then sank by 64.85% to $19.8 million in 2023, then gained by 10.6% to $22.0 million in 2024, then surged by 53.89% to $33.8 million in 2025, then climbed by 28.71% to $43.5 million in 2026.
• Business Quant data shows TSHA's Operating Expenses at $43.5 million in Q1 2026, $33.8 million in Q4 2025, and $34.0 million in Q3 2025.